Unifying Threads: ASH and EHA Collaborate to Support Hematologists
Editor’s Note: This edition of this column is special as it comes from two association presidents: ASH’s Belinda R. Avalos, MD, and Konstanze Döhner, MD, p
Related Articles
Platelet NLRP6 protects against microvascular thrombosis in sepsis
Key PointsNLRP6 deletion enhances platelet NF-κB signaling and granule secretion, promotes microthrombosis, and shortens survival in sepsis.NLRP6 promotes
Visualizing amyloidosis: The role of radionuclide imaging in systemic amyloidosis
Hematologists have a significant role in the diagnosis and management of light chain (AL) amyloidosis and are also frequently involved in diagnosing transt
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Key Points. Epcoritamab and glofitamab had an ORR and CRR of 51.7% and 25.4%, respectively; median PFS was 2.5 months, and median OS was 7.8…
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations
Richter transformation of chronic lymphocytic leukemia (CLL) is a rare but aggressive complication with persistently poor outcomes. In this Special Report,
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Key Points. Epcoritamab and glofitamab had an ORR and CRR of 51.7% and 25.4%, respectively; median PFS was 2.5 months, and median OS was 7.8…
Type 1 von Willebrand disease: does it need a sibling?
In this issue of Blood, Atiq et al present laboratory and clinical data on patients with “low von Willebrand factor” (low VWF) where patients had…
PROTACtion against BCL-xL in post-MPN AML
In this issue of Blood, Wang et al test the efficacy of a B-cell lymphoma–extra large (BCL-xL) degrading molecule (DT2216) in a distinct subtype of…
Welcome! You are invited to join a meeting: QITI Virtual Training Workshop. After registering, you will receive a confirmation email about joining the meeting.
Welcome! You are invited to join a meeting: QITI Virtual Training Workshop. After registering, you will receive a confirmation email about joining the meeting.
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Key PointsHierarchical risk stratification acknowledges poor survival of 92% of TP53mut MNs compared with 36.5% by WHO-5 and 80.7% by ICC.MDS-EB1 and -EB2
Weathering the HLH storm and redesigning clinical trials
In this issue of Blood, Zhou et al present results of a prospective phase 2 trial demonstrating that early administration of ruxolitinib plus dexamethasone